You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

248 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Drug
Other Name(s): Gleevec®
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Drug
Other Name(s): Camptosar®
Dec 1969
Drug
Other Name(s): Sarclisa®
Dec 1969
Drug
Other Name(s): Opdivo®
Oct 2024
Drug
Other Name(s): Abraxane®
Dec 1969
Drug
Other Name(s): Opdualag™
Nov 2024
Drug
Other Name(s): Zejula
Mar 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Mar 2025

Pages